Form 4: Royalty Pharma CFO Sells Over 243K Shares in Planned Transactions

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, reported the sale of 243,541 Class A Ordinary Shares through a pre-arranged 10b5-1 trading plan.

Summary

• Terrance P. Coyne, Executive Vice President and Chief Financial Officer of Royalty Pharma plc (RPRX), reported sales of Class A Ordinary Shares.
• A total of 243,541 Class A Ordinary Shares were sold across multiple transactions between February 2, 2026, and February 4, 2026.
• The sales were executed pursuant to a Rule 10b5-1 plan adopted by Mr. Coyne on August 8, 2025.
• On February 2, 2026, 108,424 shares were sold at a weighted average price of $42.0839 per share, with prices ranging from $41.45 to $42.37.
• On February 3, 2026, 114,954 shares were sold at a weighted average price of $42.8432 per share, with prices ranging from $42.35 to $43.03.
• On February 4, 2026, 20,163 shares were sold at a weighted average price of $43.2928 per share, with prices ranging from $43.11 to $43.51.
• Following these transactions, Mr. Coyne and family vehicles continue to hold significant indirect beneficial ownership, including limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,807,277 Class A Ordinary Shares, in addition to other direct and indirect Class A Ordinary Shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales were pre-planned under a 10b5-1 plan, which typically indicates routine financial management rather than a change in the executive's outlook on the company's fundamentals.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-scheduled sales for diversification or liquidity rather than a reaction to specific non-public information.
• The weighted average sale prices for the Class A Ordinary Shares generally increased over the three days of transactions, from $42.0839 to $43.2928.

Negatives

• Insider selling, even if planned, can sometimes be interpreted by some investors as a signal that the insider believes the stock may be fully valued, though this is often an oversimplification for 10b5-1 plans.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are a common practice among corporate executives in the pharmaceutical and biotechnology sectors. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, providing liquidity and diversification while mitigating concerns about trading on material non-public information. Such transactions are generally viewed as routine and less indicative of management's outlook on the company's immediate prospects compared to unplanned sales.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan by an executive like Terrance P. Coyne aligns with best practices in corporate governance, similar to executives at major pharmaceutical companies such as Pfizer or Johnson & Johnson, who frequently utilize such plans for managing their equity compensation.
• The reported sales represent a portion of the executive's overall holdings, which is typical for diversification strategies, rather than a complete divestment, which might raise more significant concerns.

Related Party Transactions

• The reported sales of Class A Ordinary Shares were conducted by Terrance P. Coyne, an Executive Vice President and Chief Financial Officer of Royalty Pharma plc, making these transactions related party dealings.
• Indirect beneficial ownership is held through entities such as TPC RP 2021, LLC, TPC RP EPA1 LLC, and through a spouse's IRA and spouse, which are considered related parties.

Stakeholder Impact

• Shareholders: The sale by a key executive could lead to minor short-term market speculation, but the pre-planned nature of the sales under a 10b5-1 plan generally mitigates significant negative sentiment.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

A single insider sale, particularly one executed under a pre-arranged 10b5-1 plan, is generally not considered a strong indicator for a 'buy' or 'sell' recommendation. Such sales are often for personal financial planning, diversification, or liquidity. Given the routine nature of these transactions and the executive's continued significant holdings, a 'hold' recommendation is appropriate, as this event alone does not fundamentally alter the investment thesis for Royalty Pharma plc.

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, Share Sale, CFO, Terrance P. Coyne, 10b5-1 Plan, Equity Sales